Cinctive Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Cinctive Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,700	Closed	-$826K	–	401
2025 Q2	$826K	Buy	+47,700	New	+$883K	0.04%	279
2025 Q1	–	Sell	-86,991	Closed	-$2.78M	–	315
2024 Q4	$2.78M	Buy	+86,991	New	+$2.62M	0.14%	190
2024 Q3	–	Sell	-37,875	Closed	-$1.45M	–	384
2024 Q2	$1.45M	Buy	37,875 +2,881	+8%	+$130K	0.07%	274
2024 Q1	$2.06M	Buy	34,994 +29,046	+488%	+$1.85M	0.1%	216
2023 Q4	$356K	Buy	+5,948	New	+$302K	0.02%	326
2022 Q3	–	Sell	-31,654	Closed	-$1.43M	–	464
2022 Q2	$1.43M	Buy	31,654 +3,600	+13%	+$164K	0.06%	349
2022 Q1	$1.43M	Buy	28,054 +502	+2%	+$22.2K	0.05%	366
2021 Q4	$1.3M	Sell	27,552 -23,448	-46%	-$923K	0.06%	366
2021 Q3	$1.68M	Buy	+51,000	New	+$2.87M	0.08%	328

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cinctive Capital Management's APLS Position: Q3 2025 in Review

Cinctive Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 47,700 shares — an estimated $826K sold.

Cinctive Capital Management first reported a position in APLS in Q3 2021 and held it in 9 quarters. The position peaked at $2.78M in Q4 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

Cinctive Capital Management reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Cinctive Capital Management sold 47,700 Apellis Pharmaceuticals shares in Q3 2025, an estimated $826K.
Cinctive Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Cinctive Capital Management's Apellis Pharmaceuticals position peaked at $2.78M in Q4 2024.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.